NDA 206406 · Veloxis Pharms INC
Envarsus Xr
Tacrolimus · Oral
OrphanLast checked: Nov 19, 2026Latest source record: Apr 8, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Jul 10, 2015
Approved uses
2
Original approval plus efficacy supplements
Registered trials
1,405
234 Phase 3, 122 recruiting
FAERS reports
131,679
118,245 serious, 20,659 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: MALIGNANCIES AND SERIOUS INFECTIONS Increased risk for developing serious infections and malignancies with ENVARSUS XR or other immunosuppressants that may lead to hospitalization or death [see Warnings and Precautions (5.1 , 5.2 )]. WARNING: MALIGNANCIES AND SERIOUS INFECTIONS See full prescribing information for complete boxed warning. Increased risk for developing serious infections and malignancies with ENVARSUS XR or other immunosuppressants that may lead to hospitalization or death. ( 5.1 , 5.2 )
What it is approved for
From the label in effect Feb 26, 2025.
ENVARSUS XR is a calcineurin-inhibitor immunosuppressant indicated for: The prophylaxis of organ rejection in de novo kidney transplant patients in combination with other immunosuppressants ( 1.1 ) The prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants ( 1.2 ) 1.1 Prophylaxis of Organ Rejection in De Novo Kidney Transplant Patients ENVARSUS XR is indicated for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants [see Clinical Studies (14.1) ]. 1.2 Prophylaxis of Organ Rejection in Stable Kidney Transplant Patients Converting from Immediate-Release Formulations ENVARSUS XR is indicated for the prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations, in combination with other immunosuppressants [see Clinical Studies (14.2) ].
Mechanism: Tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin (an ubiquitous mammalian intracellular enzyme) is then formed and the phosphatase activity of calcineurin inhibited. Such inhibition prevents the dephosphorylation and translocation of various factors such as the nuclear factor of activated T-cells (NF-AT) and nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB). Tacrolimus inhibits the expression and/or production of several cytokines that include interleukin (IL)-1 beta, IL-2, IL-3, IL-4, IL-5, IL-6,...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 19, 2018 Supplement 7 · Efficacy OrphanLabelLetter
- Jul 10, 2015 Original approval · Type 3 - New Dosage Form OrphanLabelReviewLetter
3 products under this application
- ENVARSUS XR · TACROLIMUS EQ 1MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
- ENVARSUS XR · TACROLIMUS EQ 4MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
- ENVARSUS XR · TACROLIMUS EQ 0.75MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tacrolimus" as an intervention, any sponsor and status, largest first.
- Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP PancreatitisPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT05252754 · 4,874 participants (planned) · Start Jan 18, 2023 · Primary completion Dec 2026
Drug: Tacrolimus capsule; Placebo and 1 more · For: Post-ERCP Acute Pancreatitis
Sites: Baltimore, Maryland; Hyderabad, India; Kolkata, India · 5 sites in all
- Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01950819 · 2,037 participants · Start Dec 3, 2013 · Primary completion Feb 1, 2017
Drug: Induction therapy; Corticosteroids and 2 more · For: End Stage Renal Disease (ESRD); Chronic Kidney Disease (CKD); Hemodialysis and 2 more
Sites: Birmingham, Alabama; Loma Linda, California; Los Angeles, California · 184 sites in all
- A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney RejectionPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00717470 · 1,252 participants · Start May 14, 2008 · Primary completion Mar 2, 2010
Drug: Prograf®; Advagraf® and 3 more · For: Kidney Transplantation
Sites: Buenos Aires, Argentina; Córdoba, Argentina; Innsbruck, Austria · 110 sites in all
- Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney TransplantationPivotal-lookingCompleted
Hospital do Rim e HipertensãoAcademic, hospital or other
NCT03468478 · 1,209 participants · Start Jun 18, 2017 · Primary completion Mar 18, 2021
Drug: Sirolimus; Everolimus and 1 more · For: Kidney Transplant Infection
Sites: São Paulo, Brazil
- A Study Looking at Diabetes in Kidney Transplant Recipients Receiving Immunosuppressive Regimen With or Without SteroidsPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT01304836 · 1,166 participants · Start Jan 22, 2011 · Primary completion May 22, 2013
Drug: Advagraf; Mycophenolate Mofetil and 2 more · For: Kidney Transplantation
Sites: Perth, Australia; Sydney, Australia; Brussels, Belgium · 100 sites in all
- Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised TrialPivotal-lookingRecruiting
University of EdinburghAcademic, hospital or other
NCT04302870 · 1,150 participants (planned) · Start Feb 27, 2020 · Primary completion Dec 2030
Drug: Memantine Hydrochloride Oral Solution; Trazodone Hydrochloride oral solution and 4 more · For: Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Sites: Portadown, United Kingdom; Aberdeen, United Kingdom; Birmingham, United Kingdom · 22 sites in all
- To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)Pivotal-lookingCompleted
Glenmark Pharmaceuticals Ltd. IndiaIndustry
NCT02601703 · 1,110 participants · Start Aug 2015 · Primary completion Oct 2016
Drug: Tacrolimus Ointment 0.1%; Protopic® ointment, 0.1% and 1 more · For: Atopic Dermatitis
Sites: Tempe, Arizona; Anaheim, California; Bell Gardens, California · 60 sites in all
- Fixed Dose MMF vs Concentration Controlled MMF After Renal TransplantationPivotal-lookingCompleted
Erasmus Medical CenterAcademic, hospital or other
NCT00166244 · 901 participants · Start May 2003 · Primary completion Mar 2005
Drug: Mycophenolate Mofetil · For: De Novo Renal Transplant Recipient.
Sites: New Lambton, Australia; Brisbane, Australia; Clayton, Australia · 67 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use13,632
- drug ineffective9,158
- product use in unapproved indication6,247
- drug interaction5,771
- acute kidney injury5,731
- diarrhoea4,761
- transplant rejection4,365
- cytomegalovirus infection4,225
- pyrexia3,958
- covid-193,872
- toxicity to various agents3,789
- pneumonia3,755
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 169 |
| 2005 | 219 |
| 2006 | 259 |
| 2007 | 555 |
| 2008 | 951 |
| 2009 | 1,053 |
| 2010 | 1,201 |
| 2011 | 2,205 |
| 2012 | 2,459 |
| 2013 | 1,608 |
| 2014 | 2,523 |
| 2015 | 3,011 |
| 2016 | 4,273 |
| 2017 | 6,324 |
| 2018 | 9,468 |
| 2019 | 9,832 |
| 2020 | 11,792 |
| 2021 | 11,245 |
| 2022 | 11,517 |
| 2023 | 12,900 |
| 2024 | 14,007 |
| 2025 | 13,919 |
| 2026 | 10,189 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Envarsus XR (Tacrolimus)
2024 spending
$16.9M
Beneficiaries
3,091
19,015 claims
Per beneficiary
$5,459
$11.03 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $6,260,513 |
| 2021 | $7,870,982 |
| 2022 | $10,310,900 |
| 2023 | $13,046,575 |
| 2024 | $16,874,072 |
Part B: Envarsus Xr (Tacrolimus) · HCPCS J7503
2024 spending
$120M
Beneficiaries
15,740
170,798 claims
Per beneficiary
$7,627
2024 ASP limit $1.75 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $84,669,517 |
| 2021 | $102,552,113 |
| 2022 | $107,358,459 |
| 2023 | $114,823,107 |
| 2024 | $120,049,348 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.
Chu DK, Chu AWL, Rayner DG, et al. · J Allergy Clin Immunol 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Topical anti-inflammatory treatments for eczema: network meta-analysis.
Lax SJ, Van Vogt E, Candy B, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis.
Aruljothy A, Singh S, Narula N, et al. · Aliment Pharmacol Ther 2023 · Meta-Analysis, Systematic Review
- Topical Anti-Inflammatory Treatments for Eczema: A Cochrane Systematic Review and Network Meta-Analysis.
Lax SJ, Van Vogt E, Candy B, et al. · Clin Exp Allergy 2024 · Systematic Review, Network Meta-Analysis
- Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis.
Devasenapathy N, Chu A, Wong M, et al. · Lancet Child Adolesc Health 2023 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Metabolic Sequelae of Everolimus Treatment After Cardiac Transplant: A Hypothesis-Generating Study.
Raven LM, Muir CA, Pouliopoulos J, et al. · Heart Lung Circ 2023 · Randomized Controlled Trial
Sponsor: Veloxis Pharms INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.